AUTONOMIX MEDICAL, INC.

Highlights Autonomix Medical, Inc.

Equities

AMIX

US05330T1060

Market Closed - Nasdaq Other stock markets 15:59:51 2024-05-23 EDT			5-day change	1st Jan Change
2.39 ^USD	-5.91%		-11.15%	0.00%

04-25	Autonomix Enters into Agreement with Noisefigure Research, Inc. to Develop Next Generation of Its Proprietary Microchip	CI
04-16	Autonomix Medical Secures US Patent for Catheter-Based Technology to Treat Cancer-Related Pain	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Autonomix Enters into Agreement with Noisefigure Research, Inc. to Develop Next Generation of Its Proprietary Microchip	04-25	CI
Autonomix Medical Secures US Patent for Catheter-Based Technology to Treat Cancer-Related Pain	04-16	MT
Autonomix Medical, Inc. Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation	04-09	CI
Autonomix Medical, Inc. Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market	03-14	CI
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market	03-06	CI
Autonomix Medical, Inc. Secures Principal Investigators and Completes Clinical Training for First Human Study	02-22	CI
Autonomix Medical, Inc. Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market	02-16	CI
Autonomix Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Earnings Overshadow Potential Bond Surge Concerns	02-07	MT
Autonomix Gets Approval to Start Clinical Trial for Pancreatic Cancer Pain Treatment in Uzbekistan	02-06	MT
Autonomix Re-Acquires Sensing Technology from Impulse Medical for $8 Million in Stock	01-30	MT
Autonomix Medical, Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	01-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer